Medable
Medable is a Decentralized Clinical Trials company founded in 2012 and based in Palo Alto, United States. It has raised $521M in total funding, most recently a Series D in 2021 at a $2.1B valuation.
Founded in 2012 in Palo Alto by Stanford-trained physician-scientist Michelle Longmire alongside Tim Smith and James Sas, Medable builds software that lets pharmaceutical sponsors and CROs run hybrid and fully decentralized clinical trials. Its platform spans electronic consent, electronic clinical outcome assessment (eCOA/ePRO), televisits, BYOD/wearables data capture and an AI-powered Study Studio that compresses study build timelines. Medable raised a $304M Series D in October 2021 led by Blackstone Growth, GSR Ventures and Tiger Global at a $2.1B valuation, bringing total capital raised to roughly $521M. The company has since gone through multiple rounds of layoffs as it pursues profitability and is investing heavily in agentic AI tools for trial operations.
Medable was the first decentralized clinical trial platform to reach unicorn status and remains one of the most widely deployed eConsent and eCOA stacks in pharma — making it a bellwether for whether DCT software can survive the post-pandemic normalization and the new wave of AI-native trial operations tools.
medable.com ↗·Decentralized Clinical Trials·
United States·private 
